Amino acid sequences of antibodies can be generated using a generative adversarial network that includes a first generating component that generates amino acid sequences of antibody light chains and a second generating component that generates amino acid sequences of antibody heavy chains. Amino acid sequences of antibodies call be produced by combining the respective amino acid sequences produced by the first generating component and the second generating component. The training of the first generating component and the second generating component can proceed at different rates. Additionally, the antibody amino acids produced by combining amino acid sequences front the first generating component and the second generating component may be evaluated according to complentarity-determining regions of the antibody amino acid sequences. Training datasets may be produced using amino acid sequences that correspond to antibodies have particular binding affinities with respect to molecules, such as binding affinity with major histocompatibility complex (MHC) molecules.

Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.

Disclosed herein are methods and systems of utilizing sequencing reads for detecting and quantifying the presence of a tissue type or a disease type in cell-free DNA prepared from blood samples.

Disclosed herein are methods and systems of utilizing sequencing reads for detecting and quantifying the presence of a tissue type or a disease type in cell-free DNA prepared from blood samples.

This application discloses a method and apparatus for detecting a molecule binding site, an electronic device, and a storage medium, relating to the field of computer technologies. According to one embodiment, the method includes: obtaining 3D coordinates of at least one site in a target molecule; for each site, obtaining a prediction probability indicating a possibility of the each site being a binding site via a site detection model; and determining a binding site from the at least one site in the target molecule based on the prediction probability of the each of the at least one site.

This application discloses a method and apparatus for detecting a molecule binding site, an electronic device, and a storage medium, relating to the field of computer technologies. According to one embodiment, the method includes: obtaining 3D coordinates of at least one site in a target molecule; for each site, obtaining a prediction probability indicating a possibility of the each site being a binding site via a site detection model; and determining a binding site from the at least one site in the target molecule based on the prediction probability of the each of the at least one site.

Methods, computer-accessible medium, and systems for generating a genome wide probe map and/or a genome wide haplotype sequence are provided. In particular, a genome wide probe map can be generated by obtaining a plurality of detectable oligonucleotide probes hybridized to at least one double stranded nucleic acid molecule cleaved with at least one restriction enzyme, and detecting the location of the detectable oligonucleotide probes. For example, genome wide haplotype sequence can be generated by analyzing at least one genome wide restriction map in conjunction with at least one genome wide probe map to determine distances between restriction sites of the genome wide restriction map(s) and locations of detectable oligonucleotide probes of the genome wide probe map(s) and defining a consensus map indicating restriction sites based on the genome wide restriction map(s) and/or locations of detectable oligonucleotide probes based on each of the genome wide probe map(s).

This invention relates to a method and system for predictively evaluating a water-insoluble material even without solubility measurement experiments.